Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Russell

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
The Lancet. Oncology|March 29, 2012
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trialNicholas D James, Matthew R Sydes, Malcolm D Mason, et al.
European Urology|July 3, 2014
Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trialGerhardt Attard, Matthew R Sydes, Malcolm D Mason, et al.
BJU International|June 4, 2016
Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747)Lazaros Andronis, Ilias Goranitis, Sarah Pirrie, et al.
Plos One|June 2, 2022
Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial dataCaroline S Clarke, Rachael M Hunter, Andrea Gabrio, et al.
European Urology|October 11, 2014
Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)Nicholas David James, Melissa R Spears, Noel W Clarke, et al.
JAMA Oncology|November 26, 2015
Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE TrialNicholas D James, Melissa R Spears, Noel W Clarke, et al.
European Urology|August 27, 2019
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate CancerAlex P Hoyle, Adnan Ali, Nicholas D James, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2017
Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled TrialMalcolm D Mason, Noel W Clarke, Nicholas D James, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2021
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE TrialHannah L Rush, Laura Murphy, Alicia K Morgans, et al.
Plos Medicine|June 7, 2022
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trialChris C Parker, Nicholas D James, Christopher D Brawley, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
The Lancet. Oncology|March 29, 2012
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trialNicholas D James, Matthew R Sydes, Malcolm D Mason, et al.
European Urology|July 3, 2014
Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trialGerhardt Attard, Matthew R Sydes, Malcolm D Mason, et al.
BJU International|June 4, 2016
Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747)Lazaros Andronis, Ilias Goranitis, Sarah Pirrie, et al.
Plos One|June 2, 2022
Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial dataCaroline S Clarke, Rachael M Hunter, Andrea Gabrio, et al.
European Urology|October 11, 2014
Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)Nicholas David James, Melissa R Spears, Noel W Clarke, et al.
JAMA Oncology|November 26, 2015
Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE TrialNicholas D James, Melissa R Spears, Noel W Clarke, et al.
European Urology|August 27, 2019
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate CancerAlex P Hoyle, Adnan Ali, Nicholas D James, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2017
Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled TrialMalcolm D Mason, Noel W Clarke, Nicholas D James, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2021
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE TrialHannah L Rush, Laura Murphy, Alicia K Morgans, et al.
Plos Medicine|June 7, 2022
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trialChris C Parker, Nicholas D James, Christopher D Brawley, et al.
Pageof 4